Gq alpha subunit

Domain Therapeutics to Participate at Premier Investor and Healthcare Conferences

Retrieved on: 
Monday, April 8, 2024
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, G protein-coupled receptor, Multimedia, Gq alpha subunit, Pharmaceutical industry

Domain Therapeutics (“Domain” or “the Company”), a global clinical-stage biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announced its President and Chief Executive Officer, Anthony Johnson, M.D., and its Chief Business Officer, Sean A. MacDonald, will participate in the following investor, partnering and healthcare industry conferences in April-May, 2024:

Key Points: 
  • Domain Therapeutics (“Domain” or “the Company”), a global clinical-stage biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announced its President and Chief Executive Officer, Anthony Johnson, M.D., and its Chief Business Officer, Sean A. MacDonald, will participate in the following investor, partnering and healthcare industry conferences in April-May, 2024:
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240408769768/en/
    Anthony Johnson & Sean A. MacDonald (Photo: Domain Therapeutics)
    Location: Metro Toronto Convention Centre (North Building), Toronto, Canada

Domain Therapeutics to Present Latest Data on DT-9045, a First-in-class Negative Allosteric Modulator of PAR2 for Immuno-oncology, at AACR 2024 Annual Meeting, Highlighting Clear Competitive Advantages of This Candidate

Retrieved on: 
Tuesday, March 26, 2024
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, GPCR, Gene, Immunotherapy, Patient, Immunosuppression, PAR2, ICB, Research, Tumor microenvironment, Cancer, G protein-coupled receptor, IND, AACR, Gq alpha subunit, Therapy, Drug resistance, Module (mathematics)

PAR2 is one of the genes most significantly linked to resistance against immune checkpoint blockage (ICB) and T cells dysfunction in cancer patients.

Key Points: 
  • PAR2 is one of the genes most significantly linked to resistance against immune checkpoint blockage (ICB) and T cells dysfunction in cancer patients.
  • Its upregulation across a variety of cancer types and expression on diverse cells within the tumor microenvironment underscore PAR2’s critical role in cancer development.
  • Remarkably, when compared to its most advanced competitors positioned in other therapeutic areas, this candidate has demonstrated clear differentiated features.
  • Stephan Schann, Chief Scientific Officer of Domain Therapeutics, commented: “We are excited to present our newest findings on DT-9045 at AACR.

Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy

Retrieved on: 
Tuesday, March 12, 2024
GPCR, CLD, CDMO, Organization, Partnership, Patient, CGMP, Research, Cutaneous T-cell lymphoma, Cancer, G protein-coupled receptor, CTCL, Gq alpha subunit, Therapy, CCR8, Vaccine

Under the terms of the agreement, Chime Biologics will ensure stable cell line development (CLD) and DT-7012 candidate manufacturing to support clinical trials in strategic countries.

Key Points: 
  • Under the terms of the agreement, Chime Biologics will ensure stable cell line development (CLD) and DT-7012 candidate manufacturing to support clinical trials in strategic countries.
  • Chime Biologics' first global modular facility with single-use bioprocessing technology meets international cGMP standards with proven audit track records.
  • Stephan Schann, Chief Scientific Officer of Domain Therapeutics, said: "We're thrilled to collaborate with Chime Biologics, a great scientific and manufacturing expert, to advance DT-7012, our leading anti-CCR8 candidate, to the next development stage.
  • At Domain, we prioritize precision research and innovation and embrace new partnerships with organizations that share our vision and passion to advance immuno-oncology".

Domain Therapeutics Promotes Stephan Schann as Chief Scientific Officer (CSO)

Retrieved on: 
Tuesday, February 27, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, PAR2, Multimedia, G protein-coupled receptor, Growth, Medicinal chemistry, Evotec, University, Therapy, GPCR, Gq alpha subunit, Biomedical Research, Patient, Intellectual property, Knowledge, CSO, Cancer

Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the expansion of the Company’s executive management team with the appointment of Stephan Schann as Chief Scientific Officer (CSO).

Key Points: 
  • Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the expansion of the Company’s executive management team with the appointment of Stephan Schann as Chief Scientific Officer (CSO).
  • Stephan will oversee the development of Domain’s proprietary pipeline and its highly innovative R&D center based in Strasbourg, France.
  • Stephan has also contributed significantly to the Company’s scientific achievements and strategic direction.
  • Dr. Tony Johnson, President and Chief Executive Officer of Domain Therapeutics, said: “We are thrilled to have Stephan be promoted into the role of Chief Scientific Officer.

Domain Therapeutics Further Strengthens Leadership Team With Appointment of Sean A. MacDonald as Chief Business Officer

Retrieved on: 
Thursday, February 8, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Multimedia, Molecular biology, Growth, Immune system, Gq alpha subunit, Patient, GPCR, Corporation, MBA, Business development, Business, Therapy, Senior advisor, G protein-coupled receptor, CBO, University, Cancer, Management

Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the appointment of Sean A. MacDonald as its Chief Business Officer (CBO) and member of the executive management team.

Key Points: 
  • Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the appointment of Sean A. MacDonald as its Chief Business Officer (CBO) and member of the executive management team.
  • Over the past year, Sean worked with Domain as an independent Senior Advisor, providing strategic input and support to the Company’s management team.
  • This included positions such as Chief Business Officer of iOnctura, Head of Business Development for Cosmo Pharmaceuticals, President and Chief Executive Officer of Corbin Therapeutics Inc, and Vice President of Corporate and Business development at Pharmascience Inc.
  • Dr. Tony Johnson, President and Chief Executive Officer of Domain Therapeutics, said: “This is an incredible time for Domain Therapeutics, and as the Company continues to grow, I am thrilled to officially welcome Sean to the team.

Domain Therapeutics Awarded Hospital-University Research in Health (RHU) SPRINT Consortium Grant to Progress Its Proprietary CCR8 Antibody Candidate to the Clinic

Retrieved on: 
Thursday, January 25, 2024
Technology, Biotechnology, Health, Biometrics, Other Health, Pharmaceutical, Artificial Intelligence, Oncology, Other Science, Research, Hospitals, Health Technology, Science, Clinical Trials, Patient, Therapy, G protein-coupled receptor, AP-HP, Multimedia, Fatigue, Intelligence, Medicen, Government, Cancer, Cutaneous T-cell lymphoma, Drug discovery, Quality of life, SPRINT, Survival rate, Regulatory T cell, National Cancer Institute, Disease, Study Group, Sarcoma, Hospital, GPCR, Pain, Gq alpha subunit, ANR, TME, RHU, Physician, Pharmaceutical industry

Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces it has been awarded a grant as part of the Hospital-University Research in Health (RHU) SPRINT consortium.

Key Points: 
  • Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces it has been awarded a grant as part of the Hospital-University Research in Health (RHU) SPRINT consortium.
  • View the full release here: https://www.businesswire.com/news/home/20240125583037/en/
    The SPRINT project aims to revolutionize the management of patients with CTCL and deliver a new cure paradigm as a standard-of-care.
  • The grant that we have been awarded by the RHU SPRINT consortium will support the progress of DT-7012, an anti-CCR8 monoclonal antibody which has incredible potential as a best-in-class therapeutic, into the clinic.
  • Domain was already awarded a first RHU grant, RHU CONDOR for Sarcoma, in the previous campaign, leveraging another proprietary asset.

Domain Therapeutics Strengthens Leadership Team to Spearhead Global Development and North American Expansion as the Leading GPCR Immuno-Oncology Company

Retrieved on: 
Monday, January 8, 2024
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, OrbiMed, Multimedia, AstraZeneca, Gq alpha subunit, Research, Physician, Fellow, Therapy, Cancer, GSK, PNT, University, Royal Australasian College, GPCR, Growth, Patient, Bristol Myers Squibb, Management

View the full release here: https://www.businesswire.com/news/home/20240108886645/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240108886645/en/
    Michael’s appointment as Chairman follows Laurence Rulleau and Youssef Bennani, who held the role for 9 years.
  • An industry expert with international experience leading biopharmaceutical companies, Michael is also currently the President and Chief Executive Officer of RENOGENYX.
  • As the new President and CEO, based in Boston, Tony succeeds Pascal Neuville who founded and successfully led the Company for the past 15 years.
  • Their respective expertise and track record in pioneering and leading biopharmaceutical companies will be invaluable to the Company and will support our reach and global focus.

Keiretsu Forum’s Investor Capital Expo Highlights Resilience and Opportunity in Early-Stage Investments

Retrieved on: 
Monday, October 30, 2023
Humanetics, Health, Infection, Keiretsu Forum, Orion, Pediatrics, Kidney failure, Abuse, Weissmann, Gq alpha subunit, Research, Dialysis, Orthopedic surgery, Biotechnology, Angel Capital Association, Drug discovery, VC, Ligament, Tendon, Cancer, AI, Investment, Therapy, Defense, Patient, Automation, DART, Peritoneal dialysis, Fire, Capital, Tourism, Pharmaceutical industry, Q1

Despite this backdrop, the 11th Annual Investor Capital Expo in Philadelphia on October 25, 2023, drew the participation of 200 forward-thinking accredited angel investors attending in person and virtually.

Key Points: 
  • Despite this backdrop, the 11th Annual Investor Capital Expo in Philadelphia on October 25, 2023, drew the participation of 200 forward-thinking accredited angel investors attending in person and virtually.
  • Keynote, Ron Weissman , Chair of the Angel Capital Association counselled participants that short-term demand for capital exceeds supply but, that this market correction is not a collapse.
  • Keiretsu Forum Mid-Atlantic and South-East is coming off of three consecutive years of record breaking angel member investments.
  • For more information on upcoming investor meetings and company presentations, contact Keiretsu Forum Mid-Atlantic and South-East at [email protected]

GPCR Therapeutics Announces Publication on Improving Hematopoietic Stem Cell Mobilization Using Propranolol with GPC-100

Retrieved on: 
Thursday, October 26, 2023
Stem cell, Survival, Bone pain, Gq alpha subunit, Google Store, GPCR, Multiple myeloma, Propranolol, Therapy, Hope, Health, Hematological Cancer Research Investment and Education Act, CXCR4, Sickle cell disease, Research, Cell, ASCT, Mouse, Clinical trial, Risk, Cancer, HSC, G-CSF, G protein-coupled receptor, Transplant, Bone marrow, PLOS, Tumors of the hematopoietic and lymphoid tissues, Biology, Patient, B cell, Seoul National University, Pharmaceutical industry, Microbiology

These findings strongly support the use of this combination for peripheral blood HSC harvest in autologous stem cell transplant treatment in hematological cancers.

Key Points: 
  • These findings strongly support the use of this combination for peripheral blood HSC harvest in autologous stem cell transplant treatment in hematological cancers.
  • The paper, authored in collaboration with Seoul National University’s School of Biological Sciences and Institute of Microbiology, is entitled, “GPC-100, a novel CXCR4 antagonist, improves in vivo hematopoietic cell mobilization when combined with propranolol” (1).
  • The authors highlight that GPC-100 alone shows greater mobilization efficacy than a drug already approved for stem cell mobilization.
  • Increasingly, clinicians are using Autologous Stem Cell Transplant (ASCT) to treat patients, which has improved the anti-cancer response and survival compared to conventional chemotherapy.

Piramal Pharma Solutions Launches In-Vitro Biology Capabilities at Ahmedabad Discovery Services Site

Retrieved on: 
Tuesday, October 17, 2023
Transfer, Biology, Fluorescence, PPS, Flow cytometry, Chemistry, ECL, Gq alpha subunit, G protein-coupled receptor, CDMO, FP, Research, Homogeneity and heterogeneity, Fine chemical

MUMBAI, India, Oct. 17, 2023 /PRNewswire/ -- Piramal Pharma Limited's Pharma Solutions (PPS) business, a leading Contract Development and Manufacturing Organization (CDMO), today formally announced the launch of a world-class high-throughput screening facility that augments the existing in-vitro biology capabilities at its drug discovery services site in Ahmedabad, India.

Key Points: 
  • MUMBAI, India, Oct. 17, 2023 /PRNewswire/ -- Piramal Pharma Limited's Pharma Solutions (PPS) business, a leading Contract Development and Manufacturing Organization (CDMO), today formally announced the launch of a world-class high-throughput screening facility that augments the existing in-vitro biology capabilities at its drug discovery services site in Ahmedabad, India.
  • This new expansion significantly adds primary and secondary screening capabilities of compounds prepared at the Ahmedabad site.
  • With this expansion, Piramal Pharma Solutions is uniquely positioned to provide clients with an integrated set of discovery capabilities and leverage a wide range of in-vitro screening technology tools to support its broad portfolio of research services.
  • Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions said, "Through these enhanced in-vitro biology services, our drug discovery team will be able to provide clients with decision-driving information earlier and will be an even more effective partner in the drug discovery process."